C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 215/14 (2006.01) A61K 31/41 (2006.01) A61K 31/44 (2006.01) A61K 31/47 (2006.01) A61K 31/495 (2006.01) C07D 213/30 (2006.01) C07D 213/55 (2006.01) C07D 215/18 (2006.01) C07D 235/12 (2006.01) C07D 235/20 (2006.01) C07D 239/26 (2006.01) C07D 241/42 (2006.01) C07D 263/56 (2006.01) C07D 277/30 (2006.01) C07D 277/64 (2006.01) C07D 401/14 (2006.01) C07D 413/14 (2006.01) C07D 417/14 (2006.01)
Patent
CA 2233550
Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A- COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) - OR6, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
L'invention porte sur des composés représentés par la formule (I), où W est identique à chaque occurrence, et est choisi parmi quinolyle facultativement substitué, benzothiazolyle facultativement substitué, benzoxazolyle facultativement substitué, benzimidazolyle facultativement subtitué, quinoxalyle facultativement substitué, pyridyle facultativement substitué, pyrimidyle facultativement substitué, et thiazolyle facultativement substitué; R?1¿ et R¿2? sont choisis chacun séparément parmi hydrogène, alkyle, haloalkyle, alcoxy, halogène; R?3¿ est une liaison de valence ou est choisi parmi hydrogène et alkyl; et Z est choisi parmi (a) COM, (b) CH=N-O-A-COM, (c) CH¿2?-O-N=A-COM où A est choisi parmi alkylène et cycloalkylène, et M est choisi parmi (A) un groupe métaboliquement clivable et pharmaceutiquement acceptable, (b) -OR?6¿, (c) -NR?7¿R?8¿, (d) -NR?6¿SO¿2?R?9¿, (e) -NH-Tetrazolyl, et (f) glycinyle. Ces composés inhibent la biosynthèse de leukotriène, et sont utilisés dans le traitement d'allergies et d'inflammations. L'invention porte également sur des compositions inhibant la biosynthèse de leukotriène et sur un procédé d'inhibition de la biosynthèse de leukotriène.
Bhatia Pramila
Brooks Clint D.w.
Craig Richard A.
Gunn David E.
Kolasa Theodozyj
Abbott Laboratories
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1511788